This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

peer-reviewed publication

trusted source

proofread

Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies

Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies
Neutralization screening of a large multinational cohort. a, Isolated IgGs of 2,354 HIV-1-infected individuals from a multinational study were tested against the global panel. The neutralization against each of the 12 viruses received a score between 0 and 3. Scores were later added to build neutralization strata. b, Clinical and virological characteristics of individuals from the different countries. Numbers indicate the amount of people for whom the respective characteristic was available. c, Neutralization strata of all individuals and of each respective cohort. d, Violin plots of the neutralization of participants’ IgGs against the global panel pseudoviruses. Individuals were stratified according to the strata as shown in c. Black bars indicate median, and gray bars indicate the respective quartiles. e, Average neutralization of each cohort against the respective 12 global panel viruses. f, Violin plots show the average neutralization against the whole global panel (Germany, n = 1,294; Nepal, n = 422; Tanzania, n = 475 and Cameroon, n = 163). Black bars indicate median, and dotted bars indicate the respective quartiles. One-way ANOVA with Tukey’s correction for multiple comparisons was used to compare average neutralization between groups. *P = 0.021, ***P < 0.001. g, Fold change of the mean neutralization of the respective cohorts against the global panel, when normalized to the mean activity against all 12 strains (f). Credit: Nature Medicine (2023). DOI: 10.1038/s41591-023-02582-3

An international team has for the first time researched the longevity of neutralizing antibodies in HIV-1-infected people. Currently, it is assumed that an HIV-1 vaccine can only be effective if it produces these antibodies in vaccinated humans. The findings improve understanding of the dynamics of such antibodies and are an important building block for further research into an HIV-1 vaccine.

Professor Dr. Florian Klein, Director of the Institute of Virology at the University Hospital Cologne, and Dr. Dr. Philipp Schommers, Head of the Laboratory for Antiviral Immunity at Department I of Internal Medicine of the University Hospital Cologne, were involved in the study. The publication was published under the title "Dynamics and durability of HIV-1 neutralization are determined by " in the journal Nature Medicine.

Dr. Schommers, first author of the study, reports, "We were able to show that the HIV-1 neutralization activity in patients strongly depends on the amount of virus in patients. While this dependence could be investigated in other , such as COVID-19, shortly after the initial description of the disease, the longevity of neutralizing antibodies in HIV-1 had not yet been shown in large studies."

Despite effective drugs that are the basis for treating the HIV-1 infection and can effectively prevent the transmission of the virus, over 1.2 million people are infected with HIV every year. Therefore, the development of an effective HIV-1 is still being intensely researched. So-called broadly neutralizing antibodies (bNAbs) can prevent HIV-1 infection.

Researchers are trying to induce such bNAbs through a vaccination in humans. However, this has proven to be extremely difficult. Therefore, vaccines that allow the formation of bNAbs in humans have not yet been developed. It is also unclear how long such broadly neutralizing antibodies remain in humans. However, this knowledge is extremely important in developing successful strategies for HIV-1 vaccination.

Therefore, the researchers led by Professor Klein and Dr. Schommers have investigated the HIV-1 antibody response in more than 2,300 patients from Germany, Tanzania, Cameroon, and Nepal. They identified various factors that cause patients to form neutralizing antibodies naturally. In addition, they identified so-called "elite neutralizers," i.e., HIV-1-infected individuals who build up a very potent and broadly neutralizing antibody response.

When the international research team examined HIV-1-infected individuals over time, it was then able to find out with what dynamics HIV-1 neutralizing antibodies can be sustained or the concentration of these can be further decreased in the blood. Here it was shown that the antibody response in these patients decreases over the years, but in them, highly potent bNAbs are detectable even after years. This is an important finding and indicates that a possible HIV-1 vaccine can trigger a permanent vaccine response.

More information: Philipp Schommers et al, Dynamics and durability of HIV-1 neutralization are determined by viral replication, Nature Medicine (2023). DOI: 10.1038/s41591-023-02582-3

Journal information: Nature Medicine
Citation: Another step toward the HIV-1 vaccine: Dynamics of neutralizing antibodies (2023, November 14) retrieved 4 March 2024 from https://medicalxpress.com/news/2023-11-hiv-vaccine-dynamics-neutralizing-antibodies.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Remission from HIV-1 infection: Discovery of broadly neutralizing antibodies that contribute to virus control

32 shares

Feedback to editors